PTCT - PTC Therapeutics

-

$undefined

N/A

(N/A)

PTC Therapeutics NasdaqGS:PTCT PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Location: 500 Warren Corporate Center Drive, Warren, NJ, 07059, United States | Website: https://www.ptcbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

4.325B

Cash

2.038B

Avg Qtr Burn

N/A

Short % of Float

8.02%

Insider Ownership

2.42%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
KEBILIDI™ (eladocagene exuparvovec) Details
Aromatic L-amino acid decarboxylase deficiency

Approved

Quarterly sales

Evrysdi (riskiplam) Details
Spinal muscular atrophy

Approved

Quarterly sales

Emflaza (deflazacort) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

Translarna (ataluren) Details
Duchenne muscular dystrophy

PDUFA

Approval decision

Vatiquinone (PTC743) Details
Friedreich’s Ataxia

PDUFA

Approval decision

PDUFA

Approval decision

PTC518 Details
Huntington's disease

Phase 2

Update

Vatiquinone (PTC743) Details
Epilepsy, Mitochondrial disease

Failed

Discontinued

Utreloxastat Details
Amyotrophic lateral sclerosis

Failed

Discontinued

Failed

Discontinued